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conditions, their levels increase in vascular diseases. 6 The number of erythrocyte and endothelial MVs increases in severe PET, 7 and shedding of trophoblast MVs into maternal circulation is higher in early-onset than late-onset diseases. 8 It is of interest that MVs of women with PET were found to promote vascular wall inflammation. 9 Our previous study, characterizing MVs of normal healthy pregnant (NHP) women and women with gestational vascular complications (GVCs), including HT and PET, 10 showed that trophoblast MV levels were similar in these groups. However, endothelial CD144 MVs were elevated in the GVC groups compared with the NHP cohort, which may reflect the vascular injury typical of these pathologies. There are limited data on the alteration of MV content and function in GVCs. Regulatory mechanisms controlling human trophoblast differentiation, invasion, and endothelial dysfunction remain unclear.
We hypothesize that MVs of NHP women reflect their physiological state, whereas MVs of women with GVC correspond to their pathophysiological condition, and MVs of these populations differentially affect endothelial and trophoblast cell function. The current study aimed to explore the effects of MVs on endothelial and trophoblast cells in NHP and GVC, which could potentially contribute to the elucidation of the mechanisms involved in GVC development. : Group I, pregnant women with HT (n=29; blood pressure >140/90 mm Hg without proteinuria after 20 weeks of gestation); Group II, pregnant women with mild PET (n=23; hypertension accompanied by proteinuria >300 mg per 24 hours); and Group III, pregnant women with severe PET (n=19; blood pressure elevation ≥160/110 mm Hg in presence of ≥1 of the following parameters: proteinuria [≥2.5 g in 24 hours], thrombocytopenia [<100 000 platelets/µL], pulmonary edema or cyanosis, symptoms of central nervous system dysfunction, hepatocellular injury, and HELLP syndrome [(H) hemolysis, (EL) elevated liver enzymes, (LP) low platelet count]).
Methods
MV Isolation From Blood Samples
Fifteen milliliters of peripheral venous blood were drawn from study participants into sodium citrate (3.2%) tubes; platelet-poor plasma (PPP) was obtained after 2 centrifugations (10 minutes, 1500g) within 1 hour of collection and frozen at −80°C. MVs were isolated from thawed PPP by centrifugation (1 hour, 18 000g). Supernatant liquid was discarded, and MV pellets were used for cell culture stimulation. Only part of obtained samples was used in every assay.
Cell Culture
Human umbilical vein endothelial cells (HUVECs) were isolated from umbilical cords obtained at term of normal pregnancy, according to the previously described technique.
12 Passages 4 to 8 were used for experiments.
Human term trophoblasts were obtained from term placenta of normal pregnancy (n=6). Cells were isolated and cultured as previously described. 13 Early-stage trophoblast (EST) cells isolated from second-trimester placenta were purchased from ScienCell (Carlsbad, CA). They were recultured in a modified medium containing 50% trophoblast medium with supplements (as provided by ScienCell), 22% DMEM, 22% F12, 4% FCS, 1% antibiotics (10 000 U/mL penicillin, 10 mg/mL streptomycin, 250 U/mL nystatin), and 0.0001% amphotericin B. Cells were incubated at 37°C, 5% CO 2 and used for experiments at passages 4 to 15. ESTs were seeded in 6-well tissue culture plates and cultured for 1 to 2 days until 80% confluence. Because trophoblasts are the only cells producing the human placental lactogen (hPL) hormone, trophoblast cell cultures (EST and term) were labeled with anti-hPL to ensure quality control for their content. A culture where >90% of cells were labeled with anti-hPL was considered as a pure trophoblast culture.
Antibodies and Dyes
Cells and MVs were characterized using conjugated mouse antihuman antibodies: APC-Flt-1 (VEGFR-1), PE-KDR (VEGFR-2), APCIgG1κ Isotype control (R&D Systems, Minneapolis, MN), PE-CD41, CD11a, PE-IgG1κ Isotype controls (BD Biosciences; Pharmingen, CA), FITC tissue factor (American diagnostica, Stamford, CT), CD144 (R&D Systems, Minneapolis, MN), and NDOG1-IgM (Serotec, BioRad Laboratories, Inc, United Kingdom). Additionally, rabbit anti-hPL (Epitomics, CA), anti-rabbit IgG, and anti-mouse IgM PE (Jackson, PA), antibodies against mitogen-activated protein kinases, extracellular signalregulated kinases (Erk1/2), phosphor-p44/42 mitogen-activated protein kinases (Erk1/2) (Cell signaling technology, MA), ERK 2 (6G11) (Santa Cruz Biotechnology, California), anti-β-actin (SIGMA, Missouri), and DRAQ5 (Biostatus Limited, United Kingdom) were used.
Flow Cytometry Analysis
MV size and granularity were evaluated by flow cytometer, CyAn ADP analyzer (Beckman Coulter). Forward scatter and side scatter parameters were set on logarithmic scales. The MV size was evaluated using standard Megamix (Biocytex, Marseille, France) and 0.78 µm beads (BD Biosciences; Figure S1A -S1C in the online-only Data Supplement). MV concentrations were measured using 7.5 µm count beads (Flow Cytometer Absolute Count Standard, Bangs Laboratories Inc., Indiana), as described previously. 8 . MVs were labeled with antibodies for 30 minutes, suspended in PBS containing 0.02% formaldehyde, and scanned by the CyAn ADP analyzer. EST cells were fixed and permeabilized using BD Cytofix/Cytoperm Fixation/Permeabilization Kit according to the manufacturer's instructions and were labeled with antibodies. The forward scatter and side scatter parameters were set on linear scales.
Human Angiogenesis and Inflammatory Protein Content
Protein Array
Purified MVs were resuspended in lysis buffer (20 mmol/L Tris pH=6.8, 150 mmol/L NACl, 1 mmol/L dithiothreitol, 10% glycerol, and 1% tryton [final pH=7.5]). MV protein extract was obtained from a pool of 4 specimens within each study group and quantified using the BCA protein quantification kit (Thermo Fisher Scientific Inc, Illinois). Each protein array was loaded with 25 µg of protein from the MVs lysate pool. The Human Angiogenesis Protein Antibody Array (Ray Bio, Georgia) was performed according to the manufacturer's instructions, and results were normalized to the healthy group. Membranes were analyzed using TotalLab software.
ELISA
MVs were isolated from 1 mL of PPP and lysed by freeze-thaw cycles. The ELISA kits of MMP9, VEGF-A, and PDGF (Bender MedSystems, California) were used according to the manufacturer's instructions.
Western Blot
Cells were seeded in 6-well tissue culture plates and cultured for 1 to 2 days. For each study group, MVs pelleted from 4 mL of PPP (from individual samples and from a pool of samples) were added to the cells for 15-minute incubation. Then, cells were washed and detached with 0.25% trypsin, which was neutralized with PBS+10% FCS. Cell pellet was lysed in the lysis buffer and incubated on ice for 40 minutes. Total protein was measured with the BCA protein quantification kit. Twentyfive micrograms of cell proteins were loaded on the SDS-PAGE (10%) gel followed by transfer to the polyvinylidene fluoride membrane. The by guest on August 15, 2017 http://hyper.ahajournals.org/ Downloaded from membrane was blocked and probed overnight at 4°C with primary antibodies (Erk1/2, phosphor-p44/42 Erk1/2, ERK 2, or anti-β-actin) and with secondary antibodies conjugated to horseradish peroxidase. Immunoreactive bands were detected by the enhanced chemiluminescence reagent (Thermo Fisher Scientific Inc, Illinois).
Interactions Between MVs and ESTs
ESTs were characterized using anti-hPL and CD41. MVs were labeled with antihuman PE-conjugated CD41 antibodies. Stained MVs were added to ESTs and incubated for 1 hour at 37°C. Finally, samples were fixed with 0.5% formaldehyde. Cells were scanned using the Amnis flow cytometry analysis device (Amnis, Seattle, WA). Cell fluorescent intensity was analyzed with Ideas 4.0, an ImageStream instrument. A gate was created to differentiate between cell's membrane and cytosol areas in each image. MVs were quantified as the number of spots per area and also as total fluorescence per area.
Apoptosis
TUNEL Assay
Cells (HUVEC, EST, term trophoblasts) and an MV pellet (isolated from 2 mL of PPP obtained from several individual samples) were coseeded in 24-well tissue culture plates for 20 hours. Cells treated with 50 U of DNAase (Sigma-Aldrich, Israel) for 10 minutes served as a positive control. Then, cells were washed, and the TUNEL ( terminal deoxynucleotidyl transferase dUTP nick end labeling) assay (Roche Diagnostics, Mannheim, Germany) was performed according to the manufacturer's instructions. Acquisition was performed using flow cytometry analysis device and by fluorescence microscopy. Results were expressed as percentage of TUNEL positive cells out of the total cell population in each well.
Caspase 3/7 Activity
Cells (HUVEC, EST, term trophoblasts) were seeded in 48-well tissue culture plates, and an MV pellet (isolated from 1 mL of PPP obtained from several individual samples) was added for 20-hour incubation. Cells treated with 1 μmol/L staurosporine served as a positive control. Then, cells were washed, and caspase 3/7 activity assay was performed according to the manufacturer's instructions (CASPAS 3&7 FLICA KIT, ImmunoChemistry Technology, Minnesota). Acquisition was performed using flow cytometry analysis device and by fluorescence microscopy. Results were expressed as percentage of active caspase 3/7 positive cells out of the total cell population in each well.
Bcl-2 mRNA Expression
Cells (HUVEC, EST, term trophoblasts) were seeded in 24-well tissue culture plates with or without MVs pelleted from 2 mL of PPP (obtained from individual and pool samples) and were cultured for 6 hours. Total RNA was extracted with a TRI-Reagent kit (Molecular Research Center, Cincinnati, OH). RNA concentration and purity were determined by UV absorption at 260 and 280 nm (NanoDrop). cDNA was constructed with the cDNA synthesis kit (Applied Biosystem). mRNA expressions of Bcl-2 gene were evaluated with ABI 7700TM quantitative real-time PCR system (Applied Biosystems) and compared the human housekeeping GAPDH gene. All reagents were obtained from Applied Biosystems. Results were expressed as relative quantification.
Migration Assay
Cell migration was measured using 24-transwell inserts (BD Biosciences) coated with Poly-L-Lysine. Cells (HUVEC, EST) were added to the upper chamber, whereas MVs (isolated from 1 mL of PPP obtained from individual samples in the serum-free medium) were added to the lower chamber (medium without MVs was used as control). After 24 hours, the inserts were fixed with 4% formaldehyde and stained with 0.5% crystal violet for 10 minutes each. Cells on the top of the membrane were removed, and remaining cells on the bottom side of the membrane were photographed using inverted microscopy. Additionally, several inhibitors of cell signal transduction were used to examine the involvement of MVs in trophoblast cell migration. The following inhibitors were assessed in the presence or absence of NHP-MVs: SB203580 (P38 inhibitor), SP600125 (c-Jun N-terminal kinase inhibitor), and PD98059 (MEK 1 inhibitor) and U0126 (MEK 1/2 inhibitor). The area occupied by migratory cells was calculated using the image J software.
Tube Formation Assay
HUVECs were seeded on matrigel (Sigma-Aldrich, Rehovot, Israel) in 48-well tissue culture plates with medium free of serum and growth factors. MVs were isolated from 1 mL of PPP obtained from individual samples. MVs were added to the wells for 20 hours. The wells were continuously photographed, using time lapse imaging (Zeiss, Standort Göttingen, Germany). The length of formed tubes was measured using Image-Pro Plus software (Leeds Precision Instruments, Minneapolis, MN) and was normalized to the initial cell number in each well.
Statistical Analysis
The data were analyzed using GraphPad 5 software. Results were assessed by 1-way ANOVA, Bonferroni multiple comparisons test. When only 2 groups were compared, t test was used. P<0.05 was considered statistically significant. The results were expressed as a mean±SD. The exact numbers of each performed experiment (n) appear at the bottom of each graph and in Tables (see also the Tables  in the online-only Data Supplement) .
Results
Study Population
Blood samples were collected from 183 pregnant women. All study cohorts were similar in age. The gestation period at sampling was shorter in the combined GVC group as well as each of the GVC subgroups (HT, mild or severe PET) compared with the NHP cohort, without significant differences between the GVC subgroups. There was a significant increase in systolic and diastolic blood pressure in the combined GVC and each of GVC subgroups compared with NHP, without significant differences between the GVC subgroups (Table) . Proteinuria level significantly increased in severe PET compared with HT or mild PET. Fetal weight was found to be significantly lower in the combined GVC group compared with NHP, specifically when compared with mild or severe PET; however, the APGAR score 5 minutes after birth was similar across the study groups.
The fact that all parameters apart from proteinuria level did not significantly differ between the GVC subgroups justified the use of pool GVC samples.
MV Characterization
We found a large variation in the MV numbers among the individuals in each of the groups; therefore, the MV numbers did not significantly differ between the study groups. Characterization of membrane antigen aiming to define MV cell origin demonstrated similar levels of platelet MVs (CD41) and trophoblast MVs (NDOG1) in all the groups. However, levels of endothelial MVs (CD144) and leukocyte MVs (CD11a) appeared to be low in the NHP group compared with the GVC group, without significant difference between the GVC subgroups (Table S1, Figure S2A-S2D) .
A comparing screen of MVs obtained from NHP and combined GVC group was done using the protein array, revealing differences in the content of inflammatory and angiogenic proteins. Of 43 proteins screened, 12 were not different, 2 were reduced, whereas the remaining 29 were higher in the GVC-MV compared with NHP-MV ( Figure S1A and S1B). MVs expressed comparable levels of vascular endothelial growth factor receptors (Flt-1 and KDR) and similar levels
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of matrix metalloproteinase-9, vascular endothelial growth factor A, and platelet-derived growth factor (Table S2) . Figure S3 ). Trophoblasts and shed MVs were covered with tissue factor (labeled in green) and contained nucleic acid (blue). The study population included women with normal healthy pregnancy (NHP), a combined group of pregnant women with gestational vascular complications (GVCs), and 3 subgroups of women with GVCs: pregnant women with hypertension (HT), pregnant women with mild preeclampsia/toxemia (PET), or severe PET. The data are presented as mean (SD). BP indicates blood pressure; and NS, not significant.
MV-Cell Interaction
Apoptotic Effect of MVs
Statistical significance: *NHP vs total GVC; †NHP vs HT; ‡NHP vs mild PET; §NHP vs severe PET; ║HT vs mild PET; ¶HT vs severe PET; #mild PET vs severe PET. Figure 1A and 1B). In addition, exposure of term trophoblasts to GVC-MVs resulted in nonsignificant reduction in Bcl-2 gene expression compared with NHP-MVs.
Migration Effects of MVs
Exposure of endothelial cells to circulating NHP-and GVCMVs induced significant cell migration without differences between the study groups (16.0±4. ) and their effects were similar to those of untreated cells (Figures 2 and S5A-S5E ). In addition, we found increased ERK phosphorylation after exposure of ESTs to NHPMVs and a lower rate of phosphorylation in the cells exposed to GVC-MVs ( Figure S5F ). To evaluate the MV involvement in cell signaling, several inhibitors of signal transduction were used. The combination of MEK1 inhibitor with NHP-MVs failed to block EST-ERK phosphorylation or cell migration (33.7±10.3%) and induced migration rate similar to that of NHP-MVs alone (Figures 2 and S5) . However, the combination of MEK1/2 inhibitor with NHP-MVs significantly reduced cell migration (10.8±4.8%; P<0.001) and demonstrated a trend to reduction in ERK phosphorylation. P38 inhibitor did not obstruct migration at any examined concentration (25-100 µmol/L). While low doses (5 µmol/L) of c-Jun N-terminal kinase inhibitor did not affect migration, its higher dose (25 µmol/L) affected cell viability and consequently prevented migration (data not shown). Figure S7 displays the diverse influence of NHP-and GVCMVs on angiogenesis. In the serum-free medium without MVs (control), HUVECs formed a small unstable network that rapidly collapsed. When HUVECs were incubated with NHP-MVs, a branched network was formed within 1 hour (Figure S6A and S6B). HUVEC incubation with GVC-MVs resulted in a small amount of tubes ( Figure S6C-S6E) . The characteristics and life span of this network were very similar to those described for the control group (Tables S1-S3 and Figures S1-S6 ).
Angiogenic Effect of MVs on Endothelial Cells
Discussion
PET is a major disorder of pregnancy characterized by an increased maternal inflammatory response and vascular dysfunction, 14 affecting placentation, trophoblast proliferation, invasion, 15 and apoptosis. The current study demonstrated that NHP women and women with GVC displayed similar levels of circulating MVs, which is in accordance with our previous report 10 and other studies. 16 However, we found that the MV protein content differed between the groups. Particularly, the GVC-MVs presented higher levels of pro-and antiangiogenic proteins and proinflammatory cytokines that may be characteristic of these pathologies. 3 As GVCs can occur at various gestational stages, the present study evaluated MV effects on different trophoblast cultures obtained at early stage and term of gestation. ESTs and term trophoblasts were found to respond differently to MVs. Although NHP-MVs increased EST survival, they induced apoptosis in term trophoblasts. In contrast, GVC-MVs did not affect EST survival but caused massive apoptosis in term trophoblasts, which indicates the involvement of MVs in placental aging and demonstrates that MVs regulate trophoblast apoptosis. In general, apoptosis pathways have a dual nature in the placenta, affecting both trophoblast survival and differentiation. Normal pregnancies are characterized by a low rate of trophoblast apoptosis that increases as gestation proceeds, whereas in PET, the hallmark is a significantly higher rate of trophoblast apoptosis and abnormal placental invasion, which could ultimately result in early delivery and pregnancy loss.
What triggers human preterm or term labor is not entirely clear. The involvement of prostaglandins and proinflammatory cytokines 17 has been suggested as a potential mechanism. It is possible that the elevation in the apoptosis rate induced by potent GVC-MVs bearing significant amounts of concentrated inflammatory cytokines, as revealed in our study, contribute in part to early delivery observed in women with GVCs.
Cell migration and invasion play a crucial part in the development of uteroplacental circulation. 4 The present study showed that endothelial and EST cell migration was induced by NHPMVs and inhibited by GVC-MVs. In our opinion, these results suggest a role of NHP-MVs in preserving endothelial and trophoblast function, whereas the GVC-MVs could be major players in the antiangiogenic milieu, potentially impairing endothelial function. 7 This may explain a mechanism of placental implantation failure at early stages of pregnancy observed in women with PET.
The current study is the first to demonstrate that MVs affect trophoblast migration through altering ERK signal transduction. Mitogen-activated protein kinase pathways are known to participate in a wide range of biological processes, and ERKs are the major modulators of trophoblast invasion and migration. 18 The present study has some limitations. Gestational HT and preeclampsia are complex pathologies, and the study population was not homogeneous. Despite a relatively large number of participants, not every assay was performed in all patients.
In conclusion, our findings demonstrate that the MV content differs in healthy and pathological gestational states. MVs play a crucial role in angiogenesis, inflammation, and apoptosis of endothelial and trophoblast cells, which affect their function and fate and can influence placental implantation and vascularization at an early gestational stage, potentially affecting pregnancy development and duration.
Perspectives
The current study, using human samples, has demonstrated that GVC-MV content reflects the perturbation in angiogenic and inflammatory proteins, characterizing this type of pathological pregnancies. MVs may affect placentation in a stage-specific pattern. At early stages of pregnancy, MVs decrease trophoblast apoptosis and enhance migration, both functions being crucial for proper placentation. Strikingly, this MV effect on ESTs is lost in women with GVC. In contrast, GVC-MVs were found to promote apoptosis of term trophoblast cells, which may suggest their involvement in preterm delivery. MVs, both shed from the syncytial surface and circulating, are localized for relatively long periods in the intervillous space as a consequence of the low shear stress in this area, thereby affecting trophoblast and endothelial function. Although larger studies are warranted to confirm these results, the contribution of MVs to the development of NHPs and GVC may pave the way to better understanding of normal pregnancy physiology and improved management of these major pathologies. 
